

Earnings hold firm; Oswego drag and leverage to recede

Metals & Mining ▶ Company Update ▶ August 05, 2026

CMP (Rs): 1,039 | TP (Rs): 1,150

Novelis delivered a strong 1Q, with adjusted EBITDA of \$516mn, 5.7% above our estimate (+12.4% qoq), and EBITDA/t of \$563. Even adjusting for the \$18mn net Oswego benefit, underlying EBITDA/t remained healthy at \$525. With Oswego operations normalizing, the earnings drag should recede, while insurance proceeds and normalization of elevated inventories should support cash conversion. We would, however, temper near-term earnings extrapolation, given unusually favorable scrap spreads, with the management retaining its medium-term normalized EBITDA/t guidance of ~\$600. As Bay Minette capex also winds down, Novelis expects to turn FCF-positive by 4QFY27, supporting leverage reduction from 4.5x to below 4x by FY27-end. We maintain ADD and TP of Rs1,150.

Core earnings remain robust as Oswego headwinds recede

Novelis reported a strong 1Q performance, with adj EBITDA of \$516 in 4Q (+12.4% qoq, 24.0% yoy), 5.7% ahead of our estimate of \$487. The beat was led by higher average aluminum prices (up 11.6% qoq) and lower shipment loss of 33kt from Oswego (already known) vs 4Q loss of 72kt; it was further supported by an estimated \$18mn net positive impact from the Oswego fires, inclusive of \$47mn business interruption insurance proceeds. Adj EBITDA/t stood at \$563 vs \$544 in 4Q. However, even on excluding the net positive impact of the Oswego fire incident, underlying business continues to perform well, with EBITDA/t of \$525. Operationally, shipments rose 8.5% qoq but declined 4.9% yoy to 916kt. Novelis reported net profit of \$164mn vs our estimate of \$181mn.

Oswego drag fading; working-capital unwind to aid cash flows

With Oswego largely back online and majority of incremental fire-related costs already absorbed, insurance receipts should exceed residual costs from 2Q onward, providing a meaningful cash-flow offset as the operational impact recedes; this would offer a meaningful tailwind to profitability over the next few quarters. However, we would not extrapolate the strong 1Q profitability, as favorable scrap spreads provided a meaningful tailwind during the quarter and are unlikely to sustain at current levels. Accordingly, the management continues to anchor medium-term normalized EBITDA/t at ~\$600. Working capital was elevated, as Novelis carried higher-than-normal inventories to mitigate supply-chain disruptions and longer transit times following the Oswego outage; this should unwind as operations normalize, aiding cash conversion.

FCF recovery to pave the way for deleveraging

Novelis reported net debt of \$7.9bn in Jun-26, with net debt-to-EBITDA rising to 4.5x vs 4.1x in Mar-26. We draw comfort from insurance recoveries expected to more than offset residual Oswego costs going forward, while working-capital normalization and tapering Bay Minette capex should support return to a positive FCF by 4QFY27, which is expected to bring down leverage below 4x by FY27-end. We maintain ADD and TP of Rs1,150.

Target Price – 12M	Jun-27
Change in TP (%)	-
Current Reco.	ADD
Previous Reco.	ADD
Upside/(Downside) (%)	10.7


Stock Data	HNDL IN
52-week High (Rs)	1,179
52-week Low (Rs)	657
Shares outstanding (mn)	2,247.2
Market-cap (Rs bn)	2,335
Market-cap (USD mn)	24,544
Net-debt, FY27E (Rs mn)	965,543.2
ADTV-3M (mn shares)	6.4
ADTV-3M (Rs mn)	6,224.4
ADTV-3M (USD mn)	65.4
Free float (%)	64.9
Nifty-50	24,624.7
INR/USD	95.1

Shareholding, Jun-26

Promoters (%)	34.7
FPIs/MFs (%)	31.4/24.1

Price Performance

(%)	1M	3M	12M
Absolute	9.0	(1.5)	51.2
Rel. to Nifty	7.4	(3.9)	51.4

1-Year share price trend (Rs)**Hindalco: Financial Snapshot (Consolidated)**

Y/E Mar (Rs mn)	FY25	FY26	FY27E	FY28E	FY29E
Revenue	2,384,960	2,749,440	3,390,416	3,460,784	4,052,521
EBITDA	354,960	380,970	466,592	495,603	582,192
Adj. PAT	168,810	203,540	225,047	233,994	286,528
Adj. EPS (Rs)	75.9	91.5	101.1	105.2	128.8
EBITDA margin (%)	14.9	13.9	13.8	14.3	14.4
EBITDA growth (%)	38.0	7.3	22.5	6.2	17.5
Adj. EPS growth (%)	66.5	20.6	10.6	4.0	22.5
RoE (%)	14.7	15.6	15.3	13.9	14.9
RoIC (%)	14.3	15.1	14.5	13.3	14.6
P/E (x)	14.4	17.2	11.0	7.9	8.1
EV/EBITDA (x)	7.2	6.7	5.5	5.2	4.4
P/B (x)	1.9	1.7	1.5	1.3	1.1
FCFF yield (%)	1.5	(7.8)	(2.8)	2.6	4.2

Source: Company, Emkay Research

Akhilesh Kumar
 akhilesh.kumar@emkayglobal.com
 +91-22-66121262
Vishesh Dhoka
 vishesh.dhoka@emkayglobal.com
 +91-22-66121257

Key takeaways from the conference call

Balance sheet

- Net leverage currently at 4.5x, with liquidity solid at \$2.1bn—\$1.1bn in cash and \$1.0bn available under committed credit facilities.
- The company entered into a new \$500mn unsecured term loan in Jul-26 at 'pretty attractive rates' for additional flexibility during the peak investment phase.
- Leverage expected to increase 'very slightly' before beginning the deleveraging journey; the management is confident of leverage dropping below 4.0x by FY27-end.
- No additional borrowing planned after the Jul-26 term loan; focus firmly on deleveraging as Bay Minette Capex winds down.

Cash flow guidance

- Working capital is currently elevated due to long supply chains (sourcing from multiple global plants to support North America) and inability to process returned/generated scrap; expected to normalize by end of calendar year as Oswego reaches full production, releasing cash quarter by quarter.
- The company expects to return to an FCF-positive position by the end of 4QFY27.
- Full-year capex guidance: \$2.1-2.4bn, including ~\$350mn for maintenance capital.

Oswego fire – recovery update

- Insurance recoveries received through the end of 1Q at \$300mn; additional ~\$200mn expected in 2Q.
- Ultimate net cash to be absorbed by Novelis estimated at ~\$600mn; ~\$800mn gap to be recovered via future insurance over 12+ months.
- Insurance process is expected to extend into next FY; insurers cooperating closely.
- The management maintains guidance on total shipment loss (150-200kt), EBITDA impact (\$101-150mn), and pre-recovery cash flow impact (\$1.7bn).
- Restart was used as an opportunity to strengthen global operating standards based on world-class manufacturing principles.

Bay Minette plant

- Bay Minette commissioning process is underway; transition from construction to production is expected through approximately Nov-26.
- Customer qualification is expected to take roughly two months; commercial coils to be shipped in early-CY27. Commercial shipments are expected to commence in 1QFY28.
- Initial focus will be on beverage packaging to maximize throughput, while simultaneously qualifying other products.
- Ramp-up to full 600kt capacity is expected over 18-24 months; the management is 'very confident' that all produced volume can be sold commercially.
- Approximately 180kt of capacity is still available to be contracted; the management is confident of filling full capacity across beverage packaging, automotive, and high-value products over ramp-up.
- Positive EBITDA is expected to be generated in FY28; EBITDA/t expected above \$1,000.
- Startup costs of up to \$150mn are expected during the ramp-up period (below EBITDA line, in line with US GAAP).
- Total capital cost remains in the order of \$5bn; \$3.8bn spent through the end of 1Q.

This report is intended for Team White Marque Solutions (team.emkay@whitemarquesolutions)

Scrap spread

- Favorable scrap and aluminum prices have driven EBITDA improvements through cost savings, improved scrap prices, and cost efficiency initiatives.
- Metal benefit is a key tailwind, but will pull back as prices normalize; the management acknowledged this as the key 'watch factor' in sustaining EBITDA improvement.
- Cost savings (targeting \$350-400mn by FY28-end) will grow to partially offset any metal benefit pullback over time.
- South America benefiting from favorable metal spreads, higher premiums, and easier scrap availability; the management suggests \$900-1,000/t as a more normal range for sustainable EBITDA in the region.

Tariff impact

- Net tariff headwind of ~\$70mn driven by higher inter-regional imports (subject to Section 232 tariffs) used to substitute for lost Oswego production.
- Tariff impact should normalize toward zero as Novelis has sufficient onshore capacity; it expects normalization as Oswego ramp-up reduces import dependence.

Beverage packaging pricing, and contracting

- Long-term contracts for Bay Minette capacity extend through the end of the decade; the company had step-up pricing in prior years.
- North American contracts in CY26 are seeing typical inflationary-rate price increases (rather than further step-ups).

Structural cost reduction program

- The company achieved over \$225mn in run-rate savings to date.
- Ultimate target: \$350-400mn in total savings by FY28-end; sourced from leaner organization structure, technology-enabled process improvements, labor productivity, energy and variable cost optimization, procurement savings, and improved asset effectiveness.

Outlook

- Normalized EBITDA anchor: \$600/t at normalized metal prices; management 'confidently heading towards that', aided by cost efficiency programs.
- All three major parallel catalysts converging: Oswego returning to full capacity, Bay Minette ramping up, working capital releasing, and continued insurance recoveries.

This report is intended for Team White Marque Solutions (team.emkay@whitemarquesolutions)

Hindalco: Consolidated Financials and Valuations

Profit & Loss					
Y/E Mar (Rs mn)	FY25	FY26	FY27E	FY28E	FY29E
Revenue	2,384,960	2,749,440	3,390,416	3,460,784	4,052,521
Revenue growth (%)	10.4	15.3	23.3	2.1	17.1
EBITDA	354,960	380,970	466,592	495,603	582,192
EBITDA growth (%)	38.0	7.3	22.5	6.2	17.5
Depreciation & Amortization	88,640	91,540	107,718	118,761	129,657
EBIT	266,320	289,430	358,874	376,842	452,535
EBIT growth (%)	49.2	8.7	24.0	5.0	20.1
Other operating income	-	-	-	-	-
Other income	27,080	28,890	29,757	31,245	32,807
Financial expense	34,190	34,800	46,309	51,851	54,580
PBT	232,130	254,630	312,565	324,991	397,955
Extraordinary items	(8,790)	(69,630)	(14,536)	57,656	0
Taxes	63,350	51,050	87,518	90,998	111,427
Minority interest	0	0	0	0	0
Income from JV/Associates	30	(40)	0	0	0
Reported PAT	160,020	133,910	210,511	291,649	286,528
PAT growth (%)	57.6	(16.3)	57.2	38.5	(1.8)
Adjusted PAT	168,810	203,540	225,047	233,994	286,528
Diluted EPS (Rs)	75.9	91.5	101.1	105.2	128.8
Diluted EPS growth (%)	66.5	20.6	10.6	4.0	22.5
DPS (Rs)	3.5	5.0	7.1	7.4	9.0
Dividend payout (%)	4.9	8.3	7.5	5.6	7.0
EBITDA margin (%)	14.9	13.9	13.8	14.3	14.4
EBIT margin (%)	11.2	10.5	10.6	10.9	11.2
Effective tax rate (%)	27.3	20.0	28.0	28.0	28.0
NOPLAT (pre-IndAS)	193,639	231,403	258,389	271,326	325,825
Shares outstanding (mn)	2,225	2,225	2,225	2,225	2,225

Source: Company, Emkay Research

Balance Sheet					
Y/E Mar (Rs mn)	FY25	FY26	FY27E	FY28E	FY29E
Share capital	2,220	2,220	2,220	2,220	2,220
Reserves & Surplus	1,234,870	1,363,610	1,572,903	1,790,517	2,056,988
Net worth	1,237,090	1,365,830	1,575,123	1,792,737	2,059,208
Minority interests	120	120	120	120	120
Non-current liab. & prov.	87,800	45,650	45,650	45,650	45,650
Total debt	619,310	966,590	1,091,590	1,091,590	1,091,590
Total liabilities & equity	2,048,730	2,496,670	2,830,963	3,048,577	3,315,048
Net tangible fixed assets	1,087,620	1,388,570	1,692,128	1,947,865	2,126,452
Net intangible assets	326,480	379,300	379,300	379,300	379,300
Net ROU assets	25,430	29,900	29,900	29,900	29,900
Capital WIP	270,230	475,690	475,690	475,690	475,690
Goodwill	-	-	-	-	-
Investments [JV/Associates]	183,880	238,740	238,740	238,740	238,740
Cash & equivalents	108,460	148,080	126,047	182,679	216,056
Current assets (ex-cash)	911,130	1,262,220	1,085,359	997,646	1,135,448
Current Liab. & Prov.	594,270	950,140	720,510	727,553	810,848
NWC (ex-cash)	316,860	312,080	364,849	270,093	324,600
Total assets	2,048,730	2,496,670	2,830,963	3,048,577	3,315,048
Net debt	510,850	818,510	965,543	908,911	875,534
Capital employed	2,048,730	2,496,670	2,830,963	3,048,577	3,315,048
Invested capital	1,460,730	1,604,260	1,960,586	2,121,568	2,354,662
BVPS (Rs)	555.9	613.8	707.8	805.6	925.4
Net Debt/Equity (x)	0.4	0.6	0.6	0.5	0.4
Net Debt/EBITDA (x)	1.4	2.1	2.1	1.8	1.5
Interest coverage (x)	7.8	8.3	7.7	7.3	8.3
RoCE (%)	15.4	13.8	14.4	13.6	15.0

Source: Company, Emkay Research

Cash flows					
Y/E Mar (Rs mn)	FY25	FY26	FY27E	FY28E	FY29E
PBT (ex-other income)	223,370	184,960	312,565	324,991	397,955
Others (non-cash items)	(4,680)	13,050	0	0	0
Taxes paid	(54,670)	(64,760)	(87,518)	(90,998)	(111,427)
Change in NWC	(23,210)	(142,370)	(38,233)	37,100	(54,507)
Operating cash flow	244,100	102,500	340,841	441,706	416,258
Capital expenditure	(206,490)	(300,960)	(411,276)	(374,499)	(308,245)
Acquisition of business	(120)	(1,370)	0	0	0
Interest & dividend income	8,570	12,010	0	0	0
Investing cash flow	(247,390)	(265,830)	(425,812)	(316,843)	(308,245)
Equity raised/(repaid)	(1,040)	(1,170)	0	0	0
Debt raised/(repaid)	62,370	281,930	125,000	0	0
Payment of lease liabilities	(3,970)	(3,580)	0	0	0
Interest paid	(40,440)	(47,910)	(46,309)	(51,851)	(54,580)
Dividend paid (incl tax)	(7,780)	(11,100)	(15,753)	(16,380)	(20,057)
Others	(27,300)	(17,300)	0	0	0
Financing cash flow	(18,160)	200,870	62,938	(68,230)	(74,636)
Net chg in Cash	(21,450)	37,540	(22,033)	56,632	33,377
OCF	244,100	102,500	340,841	441,706	416,258
Adj. OCF (w/o NWC chg.)	267,310	244,870	379,074	404,606	470,765
FCFF	37,610	(198,460)	(70,435)	67,207	108,013
FCFE	11,990	(221,250)	(116,744)	15,356	53,434
OCF/EBITDA (%)	68.8	26.9	73.0	89.1	71.5
FCFE/PAT (%)	7.5	(165.2)	(55.5)	5.3	18.6
FCFF/NOPLAT (%)	19.4	(85.8)	(27.3)	24.8	33.2

Source: Company, Emkay Research

Valuations and key Ratios					
Y/E Mar	FY25	FY26	FY27E	FY28E	FY29E
P/E (x)	14.4	17.2	11.0	7.9	8.1
EV/CE(x)	1.4	1.1	1.0	0.9	0.8
P/B (x)	1.9	1.7	1.5	1.3	1.1
EV/Sales (x)	1.1	0.9	0.8	0.7	0.6
EV/EBITDA (x)	7.2	6.7	5.5	5.2	4.4
EV/EBIT(x)	9.6	8.8	7.1	6.8	5.6
EV/IC (x)	1.7	1.6	1.3	1.2	1.1
FCFF yield (%)	1.5	(7.8)	(2.8)	2.6	4.2
FCFE yield (%)	0.5	(9.5)	(5.0)	0.7	2.3
Dividend yield (%)	0.3	0.5	0.7	0.7	0.9
DuPont-RoE split					
Net profit margin (%)	7.1	7.4	6.6	6.8	7.1
Total asset turnover (x)	1.3	1.2	1.3	1.2	1.3
Assets/Equity (x)	1.6	1.7	1.8	1.7	1.6
RoE (%)	14.7	15.6	15.3	13.9	14.9
DuPont-RoIC					
NOPLAT margin (%)	8.1	8.4	7.6	7.8	8.0
IC turnover (x)	1.8	1.8	1.9	1.7	1.8
RoIC (%)	14.3	15.1	14.5	13.3	14.6
Operating metrics					
Core NWC days	48.5	41.4	39.3	28.5	29.2
Total NWC days	48.5	41.4	39.3	28.5	29.2
Fixed asset turnover	1.2	1.3	1.4	1.2	1.3
Opex-to-revenue (%)	85.1	86.1	86.2	85.7	85.6


Source: Company, Emkay Research

RECOMMENDATION HISTORY - DETAILS

Date	Closing Price (Rs)	TP (Rs)	Rating	Analyst
07-Jul-26	970	1,150	Add	Akhilesh Kumar
16-Jun-26	982	1,200	Add	Akhilesh Kumar
29-May-26	1,127	1,200	Add	Akhilesh Kumar
23-May-26	1,109	1,200	Add	Akhilesh Kumar
19-May-26	1,048	1,100	Buy	Akhilesh Kumar
08-Apr-26	952	1,100	Buy	Akhilesh Kumar
31-Mar-26	884	1,050	Buy	Akhilesh Kumar

Source: Company, Emkay Research

RECOMMENDATION HISTORY - TREND



Source: Company, Bloomberg, Emkay Research

This report is intended for Team White Marque Solutions (team.emkay@whitemarquesolutions)

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkayglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Disclaimer for U.S. persons only: Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

This report is intended for Team White Marque Solutions (team.emkay@whitemarquessolutions.com)

RESTRICTIONS ON DISTRIBUTION

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons¹ may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests² in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

¹ An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report:-

- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in the securities recommended in this report as of August 05, 2026
- EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report

Disclosure of previous investment recommendation produced:

- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities recommended in this report as of August 05, 2026
- EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the August 05, 2026
- EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months.
- EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- EGFSL, its affiliates and/or Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

Emkay Rating Distribution

Ratings	Expected Return within the next 12-18 months.
BUY	>15% upside
ADD	5-15% upside
REDUCE	5% upside to 15% downside
SELL	>15% downside

Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India

Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

This report is intended for Team White Marque Solutions (team.emkay@whitemarquessolutions)

OTHER DISCLAIMERS AND DISCLOSURES:**Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) :-**

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates may have co-managed public offering of securities for the subject company in the past twelve months.

This report is intended for Team White Marque Solutions (team.emkay@whitemarquesolutions.com)